Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282313 | 0.90 | HDAC1 (0.70) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL6038181 | 0.90 | HDAC6 (0.70) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL5240357 | 0.88 | HDAC6 (0.78) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL6038155 | 0.88 | HDAC6 (0.78) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL6037963 | 0.87 | HDAC6 (0.67) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL5279007 | 0.87 | HDAC6 (0.75) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL6038178 | 0.87 | HDAC6 (0.76) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL1067946 | 0.86 | HDAC6 (0.81) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL5285806 | 0.85 | HDAC6 (0.64) | HDAC1HDAC6HDAC3HDAC8HDAC4 | |
| SCHEMBL6037929 | 0.85 | HDAC6 (0.79) | HDAC1HDAC6HDAC3HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | HDAC1 1/4885HDAC6 11/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.